Cited by 674Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerHeat shock proteins research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Open access

Shangary, Sanjeev, Qin, Dongguang, McEachern, Donna, Liu, Meilan, Miller, Rebecca S., Qiu, Su, Nikolovska-Coleska, Zaneta, Ding, Ke, Wang, Guoping, Chen, Jianyong, Bernard, Denzil, Zhang, Jian, Lu, Yipin, Gu, Qingyang, Shah, Rajal B., Pienta, Kenneth J., Ling, Xiaolan, Kang, Sanmao, Guo, Ming, Sun, Yi, Yang, Dajun, Wang, Shaomeng·2008·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0708917105PMC PMC2268798

Open this paper in CoChat — free account

Abstract

We have designed MI-219 as a potent, highly selective and orally active small-molecule inhibitor of the MDM2–p53 interaction. MI-219 binds to human MDM2 with a K i value of 5 nM and is 10,000-fold selective for MDM2 over MDMX. It disrupts the MDM2–p53 interaction and activates the p53 pathway in cells with wild-type p53, which leads to induction of cell cycle arrest in all cells and selective apoptosis in tumor cells. MI-219 stimulates rapid but transient p53 activation in established tumor xenograft tissues, resulting in inhibition of cell proliferation, induction of apoptosis, and complete tumor growth inhibition. MI-219 activates p53 in normal tissues with minimal p53 accumulation and is not toxic to animals. MI-219 warrants clinical investigation as a new agent for cancer treatment.

Integrity signals

Registry

Crossref · 10.1073/pnas.0708917105

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,021
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 2

CG Maki, JM Huibregtse, PM Howley Cancer Res 56, 2649–2654 (1996).
WS el-Deiry, JW Harper, PM O'Connor, VE Velculescu, CE Canman, J Jackman, JA Pietenpol, M Burrell, DE Hill, Y Wang, et al. Cancer Res 54, 1169–1174 (1994).

Sorted by citations

Items 501–600 of 674

Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis
Zhang, Y.-W., Zhang, X., & Lu, H. (2014) · Developmental Biology · doi:10.1016/j.ydbio.2014.09.017 · Cited by 10
Efficient Synthesis of Fully Substituted Pyrrolidine-Fused 3-Spirooxindoles via 1,3-Dipolar Cycloaddition of Aziridine and 3-Ylideneoxindole
Ren, W., Zhao, Q., Zheng, C., Zhao, Q., Guo, L., & Huang, W. (2016) · Molecules · doi:10.3390/molecules21091113 · Cited by 10
A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie · doi:10.1002/ange.201000329 · Cited by 10
Self-citation
Discovery of a Potent and Selective Degrader for USP7
Pei, Y., Fu, J., Shi, Y., Zhang, M., Luo, G., Luo, X., Song, N., Mi, T., Yang, Y., Li, J. X., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202204395 · Cited by 10
D ‐Peptide‐Based Drug Discovery Aided by Chemical Protein Synthesis
Zhao, L., & Lu, W. (2011) · Israel Journal of Chemistry · doi:10.1002/ijch.201100085 · Cited by 10
New Compound Classes: Protein–Protein Interactions
Ottmann, C. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_30 · Cited by 10
Proposing novel MDM2 inhibitors: Combined physics‐driven high‐throughput virtual screening and in vitro studies
Aydın, G., Paksoy, M. N., Orhan, M. D., Avşar, T., Yurtsever, M., & Durdağı, S. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13694 · Cited by 11
NMR Screening for Lead Compounds Using Tryptophan-Mutated Proteins
Rothweiler, U., Czarna, A., Weber, L., Popowicz, G. M., Brongel, K., Kowalska, K., Orth, M., Stemmann, O., & Holak, T. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002813 · Cited by 10
Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor – LQFM030
da Mota, M. F., Cortez, A. P., Benfica, P. L., Rodrigues, B. D. S., Castro, T. F., Macedo, L. M., Castro, C. H., Lião, L. M., de Carvalho, F. S., Romeiro, L. A. S., et al. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12573 · Cited by 10
Cu( ii )/DM-Segphos catalyzed asymmetric 1,3-dipolar cycloaddition of benzoisothiazole-2,2-dioxide-3-ylidenes and azomethine ylides
Li, F., Cao, G., Gao, Y., & Teng, D. (2017) · RSC Advances · doi:10.1039/c6ra26543j · Cited by 10
-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions
Li, X., Liu, C., Chen, S., Hu, H., Su, J., & Zou, Y. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.014 · Cited by 10
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
The Ubiquitin Tale: Current Strategies and Future Challenges
Upadhyay, A., & Joshi, V. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00278 · Cited by 11
New opportunities to overcome T cell dysfunction: the role of transcription factors and how to target them
Wu, B., Koehler, A. N., & Westcott, P. M. K. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.08.002 · Cited by 9
MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1
Chen, Y., Zhang, Z.-M., Li, X., Tao, Y., Wu, S., Fang, F., Xie, Y., Liao, X., Li, G. L., Wu, D., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.13099 · Cited by 9
Efficient 1,6-addition reactions of 3-substituted oxindoles: Access to isoxazole-fused 3,3′-disubstituted oxindole scaffolds and hexahydro-1h-pyrido[2,3-b]indol-2-one scaffolds
Liu, X., Yao, Z., Wang, G., Chen, Z., Liu, X., Tian, M., Wei, Q., Zhou, Y., & Zhang, J.-F. (2018) · Synthetic Communications · doi:10.1080/00397911.2018.1454475 · Cited by 9
Self-citation
Applications of 3,5‐Dialkyl‐4‐nitroisoxazoles and Their Derivatives in Organic Synthesis #
Nagaraju, S., Sathish, K., & Kashinath, D. (2021) · ChemistrySelect · doi:10.1002/slct.202101719 · Cited by 9
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I
Witkowski, J., Polak, S., Rogulski, Z., & Pawelec, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112984 · Cited by 9
Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system
Datta, S., Bucks, M. E., Koley, D., Lim, P. X., & Savinov, S. N. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.053 · Cited by 9
Protecting-group directed stereospecific organocatalytic [3+2] cycloadditions: a facile access to chiral spirocyclic oxindoles
Tan, B., Zhang, X. K., & Zhong, G. (2014) · ARKIVOC · doi:10.3998/ark.5550190.p008.401 · Cited by 9
Cisplatin binds to the MDM2 RING finger domain and inhibits the ubiquitination activity
Cao, K., Ding, X., Sheng, Y., Wang, Y., & Liu, Y. (2020) · Chemical Communications · doi:10.1039/d0cc00203h · Cited by 9
Exploring the Effect of Hydrocarbon Cross‐Linkers on the Structure and Binding of Stapled p53 Peptides
Choudhury, A. R., Gaikwad, V., Maity, A., & Chakrabarti, R. (2025) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26793 · Cited by 9
Asymmetric Organocatalytic [3 + 2]-Cycloaddition of N-Alkoxy-4-oxo-acrylamides with Isatin-Derived Ketimines: Access to Enantioselective Synthesis of Spirooxindole-imidazolidinones
Han, J. W., Kim, Y., Kim, D., Kim, D., & Kim, S. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c01076 · Cited by 8
Chemical Synthesis of Cell-Permeable Apoptotic Peptides from in Vivo Produced Proteins
Fricke, T., Mart, R. J., Watkins, C. L., Wiltshire, M., Errington, R. J., Smith, P. J., Jones, A. T., & Allemann, R. K. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200338u · Cited by 8
Insight into the interaction mechanism of inhibitors P4 and WK23 with MDM2 based on molecular dynamics simulation and different free energy methods
Shi, S., Zhang, S., & Zhang, Q. (2014) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2014.07.002 · Cited by 8
New developments in small molecules targeting p53 pathways in anticancer therapy
Cheok, C. F., & Lane, D. P. (2008) · Drug Development Research · doi:10.1002/ddr.20261 · Cited by 8
Pd‐catalyzed decarboxylative [3 + 2] cycloaddition: Assembly of highly functionalized spirooxindoles bearing two quaternary centers
Li, T., Zhu, X., Jiang, H., Wang, Y., Zheng, N., Peng, T., Gao, R., Shi, L., Hao, X., & Song, M. (2021) · Applied Organometallic Chemistry · doi:10.1002/aoc.6516 · Cited by 8
Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination
van der Vlag, R., Ünver, M. Y., Felicetti, T., Twarda‐Clapa, A., Kassim, F., Ermiş, Ç., Neochoritis, C. G., Musielak, B., Łabuzek, B., Dömling, A. S. S., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900574 · Cited by 8
Engineering “Antimicrobial Peptides” and Other Peptides to Modulate Protein-Protein Interactions in Cancer
Rubin, S. J. S., & Qvit, N. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201021141401 · Cited by 8
Tumor Suppressor Genes
Cheng, Y. (2012) · InTech eBooks · doi:10.5772/1337 · Cited by 9
TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha
Romo, B. A., Karakyriakou, B., Cressey, L. E., Brauer, B. L., Yang, H.-J., Warren, A., Johnson, A. L., Kettenbach, A., & Miller, T. W. (2024) · Cancers · doi:10.3390/cancers16050845 · Cited by 5
Combination therapy with p53–MDM2 binding inhibitors for malignancies
Jin, Z., Shen, J., He, J.-Y., & Hu, C. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1089-7 · Cited by 7
Identification of Small Molecules Affecting p53-MDM2/MDMX Interaction by Fluorescence Polarization
Zhang, Q., & Lu, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-236-0_8 · Cited by 7
Jetzt wird es ernst: strukturbasiertes Design von Mdm2/Mdmx‐p53‐Inhibitoren
Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie · doi:10.1002/ange.201003863 · Cited by 7
MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 7
Repurposing Drugs as Novel Triple-negative Breast Cancer Therapeutics
Das, A., Agarwal, P., Jain, G. K., Aggarwal, G., Lather, V., & Pandita, D. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666211021143255 · Cited by 7
Oncoapoptotic Markers in Oral Cancer: Prognostics and Therapeutic Perspective
Jain, A., Bundela, S., Tiwari, R. P., & Bisen, P. S. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0104-5 · Cited by 7
Apoptotic Molecular Advances in Breast Cancer Management
Moela, P., & Motadi, L. R. (2015) · InTech eBooks · doi:10.5772/61654 · Cited by 7
The Development of New Spirooxindoles Targeting the p53–MDM2 Protein-Protein Interactions for Cancer Therapy
Yu, B., & Liu, H. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_8 · Cited by 6
A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study
Nag, S. A., Qin, J., Patil, S. A., Deokar, H. S., Buolamwini, J. K., Wang, W., & Zhang, R. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.08.030 · Cited by 6
Interferon‐stimulated gene 15 enters posttranslational modifications of p53
Wang, Y., Ding, Q., Lu, Y., Cao, S., Liu, Q., & Zhang, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27347 · Cited by 6
Self-citation
Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations
Shi, S., Sui, K., Liu, W., Lei, Y., Zhang, S., & Zhang, Q. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1695671 · Cited by 6
Computational-based drug design of novel small molecules targeting p53-MDMX interaction
Egbemhenghe, A. U., Aderemi, O. E., Omotara, B. S., Akhimien, F. I., Osabuohien, F. O., Adedapo, H. A., Temionu, O. R., Egejuru, W. A., Ajala, C. F., Ihunanya, M. F., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2245483 · Cited by 6
Apoptosis in Cancer
Siddik, Z. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00012-7 · Cited by 6
Triflic Acid-Catalyzed Cycloisomerization of 1,6-Enynes: Facile Access to Carbo- and Azaheterocycles
Liu, X., Wang, Y., Zhou, J., Yu, Y., & Cao, H. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b03112 · Cited by 6
Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy
Yan, D., Xu, J., Wang, X., Zhang, J., Zhao, G., Lin, Y., & Tan, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094668 · Cited by 6
Self-citation
Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation
Mochizuki, H., Goto‐Koshino, Y., Sato, M., Fujino, Y., Ohno, K., & Tsujimoto, H. (2012) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2012.04.017 · Cited by 6
Therapeutic Targeting of p53-Mediated Apoptosis Pathway in Head and Neck Squamous Cell Carcinomas: Current Progress and Challenges
Ichwan, S. J. A., Taher, M., Ohtani, K., & Ike, M.-A. (2012) · InTech eBooks · doi:10.5772/27968 · Cited by 8
Cinchona-alkaloid-catalyzed enantioselective hydroxymethylation of 3-fluorooxindoles with paraformaldehyde
Zhao, J., Ren, X., Zheng, B.-Q., Ji, J., Qiu, Z., & Li, Y. (2018) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2018.09.004 · Cited by 6
Medicinal significance of sp2/sp3 hybridized at C-3-substituted indole-containing lead molecules and FDA-approved drugs
Faiyyaz, M., Tiwari, A., Bashir, N., Nasibullah, M., Alvi, S. S., Siddiqui, M. H., & Asif, M. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03308-x · Cited by 5
A dimethylbromobenzene-cysteine stapled peptide dual inhibitor of the p53-MDM2/MDMX interactions
Jiang, W., Jin, L., Liu, M., Hou, P., & He, W. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2018.97 · Cited by 5
Self-citation
Oscillatory Behaviors of Delayed p53 Regulatory Network with microRNA 192 in DNA Damage Response
Gao, C., & Chen, F. (2021) · International Journal of Bifurcation and Chaos · doi:10.1142/s0218127421500206 · Cited by 5
Synthesis and anti-Cancer Activity of a New Hybrid Based Spirooxindole-Pyrrolidine -Thiochromene Scaffolds via [3 + 2] Cycloaddition Reaction: Computational Investigation
Barakat, A., Haukka, M., Soliman, S. M., Al‐Majid, A. M., Ali, M., Islam, M. S., Karami, A. M., Ul‐Haq, Z., & Domingo, L. R. (2022) · Polycyclic aromatic compounds · doi:10.1080/10406638.2022.2042334 · Cited by 5
Study on the expression of p53 and MMP‑2 in patients with lung cancer after interventional therapy
Zhang, X., Wang, K.-Y., Gao, J., Li, R.-J., Guan, Q.-B., & Song, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9185 · Cited by 5
Proteasome Based Molecular Strategies Against Improper Cellular Proliferation
Dubey, A. R., Kinger, S., Jagtap, Y. A., Patwa, S. M., Kumar, P., Singh, S., Kumar, A., Kumar, A., & Mishra, A. (2021) · Cellular Physiology and Biochemistry · doi:10.33594/000000439 · Cited by 5
Therapeutic considerations for Mdm2: not just a one trick pony
Lehman, J. A., Eitel, J. A., Batuello, C. N., & Mayo, L. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.11.1309 · Cited by 6
Acid Catalyzed Synthesis of Spiroindolone Scaffolds by Iso‐Pictet‐Spengler Spirocyclisation and Evaluation of their Antibacterial Activity
Dawange, M. A., Urmode, T. D., Khan, A., & Kusurkar, R. S. (2017) · ChemistrySelect · doi:10.1002/slct.201700215 · Cited by 5
Discovery of SCY45, a Natural Small‐Molecule MDM2‐p53 Interaction Inhibitor
Gong, H., An, J., Dong, Q., Li, J., Yang, W., Sun, W., Su, Z., & Zhang, S. (2019) · Chemistry & Biodiversity · doi:10.1002/cbdv.201900081 · Cited by 5
Enzymatic Desymmetrisation of Prochiral meso-1,2-Disubstituted-1,2-Diaminoethane for the Synthesis of Key Enantioenriched (−)-Nutlin-3 Precursor
Cristofori, V., Illuminati, D., Bisquoli, C., Catani, M., Compagnin, G., Turrin, G., Trapella, C., & Fantinati, A. (2024) · Molecules · doi:10.3390/molecules29143267 · Cited by 4
Design and synthesis of multitarget triazinoindole derivatives with potent antiproliferative activity: Targeting EGFR, SIRT1, MDM2, Hsp90, PI3K, p53, and caspase-9
Badawi, W. A., Ezz-ElDien, E. S., El‐Atawy, M. A., Omar, A. Z., Hamed, E. A., Ahmed, H. A., Jaremko, M., Emwas, A.-H. M., Okda, T. M., El-Readi, M. Z., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108943 · Cited by 4
Therapeutic potential of protein–protein interaction modulators in antiviral research
Kaur, G., Thapa, K., Sood, P., Rani, L., Rani, I., Gautam, R. K., Goyal, K., Ali, H., Mishra, R., Hussain, M. S., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109346 · Cited by 4
Pyrimido[4,5-b]indole Derivatives Bearing 1,2,4-oxadiazole Moiety As MDM2 Inhibitor Candidates in Cancer Treatment
Mehri, A., Mardanshahi, M., Sirous, H., Khanahmad, H., & Rostami, M. R. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0012 · Cited by 4
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia
Aptullahoğlu, E., Howladar, M., Wallis, J. P., Marr, H. J., Marshall, S. R., Irving, J. A. E., Willmore, E., & Lunec, J. (2025) · Cancers · doi:10.3390/cancers17020274 · Cited by 4
p53 E3 ubiquitin protein ligase homolog regulates p53 in vivo in the adult mouse eye lens.
Jaramillo‐Rangel, G., Ortega‐Martínez, M., Sepúlveda‐Saavedra, J., Cárdenas, O. S., & Montes‐de‐Oca‐Luna, R. (2013) · Europe PMC (PubMed Central) · Cited by 4
Case Study: Discovery of Inhibitors of the MDM2–p53 Protein-Protein Interaction
Liu, L., Bernard, D., & Wang, S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2425-7_38 · Cited by 4
Self-citation
Signification of protein p-53 isoforms and immune therapeutic success in chronic lymphocytic leukemia
Udriştioiu, A., & Nica-Badea, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.072 · Cited by 4
Protein/ Hormone Based Nanoparticles as Carriers for Drugs Targeting Protein-Protein Interactions
Al-Suhaimi, E. A., Ravinayagam, V., Jermy, B. R., Tarhini, M., & Elaı̈ssari, A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304152320 · Cited by 4
A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53
Bechill, J., Zhong, R., Zhang, C., Solomaha, E., & Spiotto, M. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154125 · Cited by 4
An antibody‐free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GST‐HDM2 recombinant protein
Costa, B., Grillone, A. F., Salvetti, A., Rocchiccioli, S., Iacopetti, P., Daniele, S., Pozzo, E. D., Campiglia, P., Novellino, E., Martini, C., et al. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1492 · Cited by 4
Model-based optimization of combination protocols for irradiation-insensitive cancers
Hat, B., Jaruszewicz-Błońska, J., & Tomasz Lipniacki, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-69380-6 · Cited by 4
Chemical adaptation: bridging synthetic chemistry with drug development
Ding, K., Li, Y., Zhou, Y., & Huang, W. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3223-4 · Cited by 3
Self-citation
Recent strategies in the synthesis of spirooxindole scaffolds (stereoselective synthesis)
Borah, B., Sharma, S., & Chowhan, L. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22324-2.00009-6 · Cited by 3
The Importance of p53 Signaling in the Response of Cells to Checkpoint Inhibitors
Eastman, A. R. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-178-3_12 · Cited by 3
Targeting the MDM2–p53 interaction as a therapeutic strategy for the treatment of cancer
Peirce, S. K. (2010) · Cell Health and Cytoskeleton · doi:10.2147/chc.s4952 · Cited by 3
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
Pujals, A., Favre, L., Gaulard, P., & Wiels, J. (2015) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s60486 · Cited by 4
MDM2 Antagonist Nutlin-3 Stimulates Global DNA Hydroxymethylation by Enhancing p53–TET1 Signaling Axis
Wu, D., Li, Y., Li, C., Zhong, S., Liu, B., Hang, H., & Wang, H. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00247 · Cited by 3
Catalytic Asymmetric [3+2]-Cycloaddition Reaction for Controlling Multiple Sterogenic Centers on Pyrrolidines
Arai, T. (2013) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.71.672 · Cited by 3
The Role of the Nucleolus in the Stress Response
Tollini, L. A., Frum, R. A., & Zhang, Y. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0514-6_12 · Cited by 3
Insight into binding modes of p53 and inhibitors to MDM2 based on molecular dynamic simulations and principal component analysis
Cheng, W.-Y., Liang, Z., Wang, W., Yi, C., Li, H., Zhang, S., & Zhang, Q. (2015) · Molecular Physics · doi:10.1080/00268976.2015.1087598 · Cited by 3
Targeting the MDM2–p53 Protein–Protein Interaction
Hardcastle, I. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00013-9 · Cited by 3
Fibrillarin: bridging ribosome biogenesis and apoptosis in cellular stress and disease
Zhang, Z., Zhang, M., Cao, Z., Zhao, H., Li, X., & Luo, P. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02220-y · Cited by 3
p53-Reactivating Molecules as Research Tools and Anticancer Drugs
Grinkevich, V. V., Warnecke, A., & Selivanova, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_13 · Cited by 2
Regulation of p53 Activity and Associated Checkpoint Controls
Post, S. M., Quintás‐Cardama, A., & Lozano, G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-178-3_11 · Cited by 2
A diastereoselective strategy for dihydrophenanthrene-fused spirooxindoles via [1,2]-phospha-Brook rearrangement
Ali, A., Harit, H. K., Behera, C., & Singh, R. P. (2024) · Chemical Communications · doi:10.1039/d4cc02215g · Cited by 2
Designer polyQ fusion proteins sequester USP7/HDM2 for modulating P53 functionality
Zhang, X., Yue, H.-W., Liu, Y., Wang, J., Duan, H.-T., Liu, Y.-H., Jiang, L., & Hu, H. (2025) · iScience · doi:10.1016/j.isci.2025.112025 · Cited by 3
Cooperation between MDM2 and MDMX in the Regulation of p53
Blaydes, J. P. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_6 · Cited by 2
New Insights into P53 Signalling and Cancer: Implications for Cancer Therapy
Nigro, C. L. (2014) · Journal of Tumor · Cited by 2
Ciblage pharmacologique de Mdm2 : bases biologiques et perspectives de radiosensibilisation
Chargari, C., Leteur, C., Ferté, C., Deberne, M., Lahon, B., Rivera, C., Bourhis, J., & Deutsch, É. (2011) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2011.02.003 · Cited by 2
Inhibition of MDM2-p53 feedback loop by various small molecules for potential cancer chemotherapy
Khan, A., & Lu, H. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.6.6196 · Cited by 2
P53: Its Role in Carcinogenesis And Also A Novel Target for Anti-Cancer Therapy
Agrawal, S. N. (2016) · IOSR Journal of Dental and Medical Sciences · doi:10.9790/0853-1509072834 · Cited by 2
Review of the Ubiquitin Role in DNA Repair and Tumorigenesis, with Emphasis in Breast Cancer Treatment; Current Data and Future Options
Mourtzoukou, D., Drikos, I. G., Goutas, N. D., & Vlachodimitropoulos, D. (2018) · InTech eBooks · doi:10.5772/intechopen.72600 · Cited by 2
Synthesis and Optimization of New 3,6-Disubstitutedindole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDMx Complex
Salah, M., Abdel‐Halim, M., Keeton, A. B., Franklin, D. A., Bauer, M. R., Boeckler, F. M., Engel, M., Hartmann, R. W., Zhang, Y., Piazza, G. A., et al. (2015) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c15-00608 · Cited by 2
PPIs as therapeutic targets for anticancer drug discovery: the case study of MDM2 and BET bromodomain inhibitors
Espadinha, M., Conway, S. J., & Santos, M. M. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818349-6.00010-8 · Cited by 2
Patients with AML with WT TP53 but defective TP53-mediated apoptosis have a dismal survival
Dubois, J., Palmer, A., King, D., Rizk, M., Bedi, K., Shedden, K. A., & Malek, S. N. (2026) · JCI Insight · doi:10.1172/jci.insight.197261 · Cited by 1
Organophotoredox‐Catalyzed [3 + 2] Cycloaddition for the Diastereoselective Synthesis of Spirocyclopentane Oxindoles
Huang, Y., & Lin, X. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202501227 · Cited by 1
Design, computational profiling, synthesis and biological evaluation of novel 1,2,4-triazole based derivatives as antioxidant and potent p53-MDM2 inhibitors
Kotadiya, D. D., Thakur, P. S., Nair, R., Prajapati, A., Patel, D. A., Patel, S. S., Kumari, S., Priya, K., & Patel, H. D. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109948 · Cited by 1
Targeting p53 Tumor Suppressor for AML Therapy
Kojima, K., & Vassilev, L. T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_7 · Cited by 1
A new approach of abnormal apoptosis as a cause of autoimmunity and malignancy
Udristioiusup, A., Iliescusup, R. G., Udristioiusup, L., & Cojocarusup, M. (2011) · Biotechnology and Molecular Biology Reviews · doi:10.5897/bmbr2011.0018 · Cited by 1
Role of P53 Gene in Oncogenesis from Chronic Lymphocytic Leukemia
Udriştioiu, A. (2016) · American Journal of Laboratory Medicine · doi:10.11648/j.ajlm.20160102.13 · Cited by 1
Protein Surface Recognition by Synthetic Molecules
Samanta, K., Jana, P., Hirschhäuser, C., & Schmuck, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12533-8 · Cited by 1

Authors: Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., Bernard, D., Zhang, J., Lu, Y., Gu, Q., Shah, R. B., Pienta, K. J., Ling, X., Kang, S., Guo, M., Sun, Y., Yang, D., & Wang, S.
Affiliations: University of Michigan (US)
*Comprehensive Cancer Center and Department of Internal Medicine and
Ascenta Therapeutics, Inc., Malvern, PA 19355
ORCID: McEachern, Donna
Liu, Meilan
Qiu, Su
Ding, Ke
Chen, Jianyong
Bernard, Denzil
Zhang, Jian
Lu, Yipin
Shah, Rajal B.
Pienta, Kenneth J.
Guo, Ming
Sun, Yi
Yang, Dajun
Wang, Shaomeng
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2008-03-11
Volume: 105
Issue: 10
Pages: 3933-3938
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0708917105
PMC: PMC2268798
OpenAlex: W1992947288
Cited by: 660
References: 42
Citations by year: 2026: 9 · 2025: 9 · 2024: 16 · 2023: 25 · 2022: 23 · 2021: 22 · 2020: 35 · 2019: 34 · 2018: 29 · 2017: 28 · 2016: 42 · 2015: 43 · 2014: 65 · 2013: 45 · 2012: 67
FWCI: 30.50
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Prostate Cancer Foundation (P30CA046592)
Leukemia and Lymphoma Society
National Institutes of Health
National Cancer Institute (R01CA121279, P50CA069568, P30CA046592)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2 inhibitors, p53 activation, p53-MDM2 interaction, selective apoptosis, tumor growth inhibition, tumor xenografts, oral anticancer drugs, cell cycle arrest
MeSH terms: Administration, Oral, Animals, Antineoplastic Agents, Cell Cycle, Humans, Indoles, Models, Molecular, Neoplasms, Protein Binding, Spiro Compounds, Time Factors, Tumor Suppressor Protein p53, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks